GBIO 2.26 Generation Bio Co.
| Range: | 0.86-4.65 | Vol Avg: | 102600 | Last Div: | 0 | Changes: | -0.05 |
| Beta: | 2.81 | Cap: | 0.15B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 12 2020 | Empoloyees: | 174 | ||
| CUSIP: | 37148K100 | CIK: | 0001733294 | ISIN: | US37148K1007 | Country: | US |
| CEO: | Dr. Cameron Geoffrey McDonough M.D. | Website: | https://generationbio.com | ||||
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow